Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

REUTERS/Andrew Kelly/File Photo Denmark's Bavarian ... 2025 Healthcare & Pharmaceuticalscategory Merck plans to launch US subcutaneous version of Keytruda on October 1 March 28, 2025 Healthcare ...

Bangladesh reported a first outbreak of highly pathogenic bird flu on a farm since 2018, the World Organisation for Animal ...

British sportswear and fashion group Frasers disclosed a 25% stake in online consumer electricals retailer AO World , a regulatory filing showed on Tuesday.

Healthcare & Pharmaceuticalscategory· March 28, 2025 Merck plans to launch US subcutaneous ... of near-copies of the blockbuster treatment. Reuters, the news and media division of Thomson ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing ... and one of the drugmaker's best-selling products. Reuters, the news and media division of Thomson Reuters, ...

(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...